MetaCap

Avalyn Pharma (AVLN) vs Silence Therapeutics Plc American Depository Share (SLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVLN-3.70%SLN+171.00%
+181%+75%-31%
Apr 30, 20261 yearNov 20, 2026
AVLN-4.83%SLN+177.84%
+188%+79%-31%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVLN versus SLN key metrics
MetricAVLNSLN
Share price$28.40$19.81
Market cap$1.26B$1.23B
1-day change-1.05%0.00%
YTD return—+225.82%
1-year return—+213.95%
5-year return—-9.95%
EPS (TTM)$-3.96$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$559.00K
Revenue growth (YoY)—-98.71%
Net income (latest FY)—$-88.61M
Gross margin—61.54%
Operating margin—-16292.84%
Net margin—-15851.88%
52-week high$40.17$19.87
52-week low$22.24$4.19
Distance from 52-week high-29.30%-0.28%
Analyst consensusstrong_buyhold
Avg. price target upside+114.79%-0.30%
Average volume352.95K2.41M
Shares outstanding44.52M62.20M
Employees5688
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Avalyn Pharma

AVLN stock →

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

About Silence Therapeutics Plc American Depository Share

SLN stock →

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

AVLN vs SLN FAQ

Which is bigger, Avalyn Pharma or Silence Therapeutics Plc American Depository Share?

Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.23B for Silence Therapeutics Plc American Depository Share (SLN).

Are Avalyn Pharma and Silence Therapeutics Plc American Depository Share in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons